ReviewChinese medicine2025
Holistic concept guided quality control of traditional Chinese medicines for optimizing bioavailability.
Review in Chinese medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Screening and Validation of Q-Markers for Daodi Authenticity ofMolecules (Basel, Switzerland) · 2026Article
- The Role of Histone Modifications in Acute Lung Injury: Molecular Mechanisms and Potential of Traditional Chinese Medicine Treatment.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Traditional Chinese medicines (TCM) exerts multiple pharmacological effects, including anti-inflammation, antioxidation, and immune regulation, etc. However, its clinical efficacy and safety depend not only on the synergy of active substances but also on the precise control of potential toxic constituents. Therefore, a clear understanding of the in vivo behavior of TCM is essential. Bioavailability, as a key indicator for evaluating the clinical efficacy and safety of TCM, are increasingly recognized as interdependent. The ultimate goal of quality control is reflected in the bioavailability observed in clinical practice, making it a critical link for ensuring consistency and safety of TCM. This review summarizes recent progress on the mechanisms and roles of bioavailability in TCM quality control, and highlights that overcoming current bottlenecks requires cross-disciplinary integration. Guided by TCM theory and a holistic perspective, quality control should focus on biological effects rather than fragmented component analysis, and shift toward systematic and integrative approaches. Adhering to these principles is fundamental for improving bioavailability, enhancing clinical potential, and ensuring the safe use of TCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.